Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Role of perforin in controlling B-cell hyperactivity and humoral autoimmunity
Andrei Shustov, Irina Luzina, Phuong Nguyen, John C. Papadimitriou, Barry Handwerger, Keith B. Elkon, Charles S. Via
Andrei Shustov, Irina Luzina, Phuong Nguyen, John C. Papadimitriou, Barry Handwerger, Keith B. Elkon, Charles S. Via
View: Text | PDF
Rapid Publication

Role of perforin in controlling B-cell hyperactivity and humoral autoimmunity

  • Text
  • PDF
Abstract

To determine the role of perforin-mediated cytotoxic T lymphocyte (CTL) effector function in immune regulation, we studied a well-characterized mouse model of graft-versus-host disease (GVHD). Induction of acute GVHD using perforin-deficient donor T cells (pfp→F1) initially resulted in features of acute GVHD, e.g., engraftment of both donor CD4+ and CD8+ T cells, upregulation of Fas and FasL, production of antihost CTL, and secretion of both Th1 and Th2 cytokines. Despite fully functional FasL activity, pfp donor cells failed to totally eliminate host B cells, and, by 4 weeks of disease, cytokine production in pfp→F1 mice had polarized to a Th2 response. Pfp→F1 mice eventually developed features of chronic GVHD, such as increased numbers of B cells, persistence of donor CD4 T cells, autoantibody production, and lupuslike renal disease. We conclude that in the setting of B- and T-cell activation, perforin plays an important immunoregulatory role in the prevention of humoral autoimmunity through the elimination of both autoreactive B cells and ag-specific T cells. Moreover, an ineffective initial CTL response can evolve into a persistent antibody-mediated response and, with it, the potential for sustained humoral autoimmunity.

Authors

Andrei Shustov, Irina Luzina, Phuong Nguyen, John C. Papadimitriou, Barry Handwerger, Keith B. Elkon, Charles S. Via

×

Figure 3

Options: View larger image (or click on image) Download as PowerPoint
Kinetics of cytokine gene expression. (a) Cytokine gene expression from ...
Kinetics of cytokine gene expression. (a) Cytokine gene expression from acute (B6wt→F1) and pfp (B6pfp→F1) GVHD mice at 10 and 28 days after parental cell transfer. (b) Cytokine gene expression from pfp GVHD mice and chronic GVHD (DBA→F1) mice at 6 weeks after cell transfer. Results are shown as fold increase over uninjected F1 mice + SE (n = 4–5 mice per group). AP < 0.01. BP < 0.05. Similar results have been seen in two additional experiments at day 10 after parental cell transfer.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts